Emergency department opioid prescriptions are associated with small increases in hospital admission and subsequent opi ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

The Waterloo Region is facing an opioid crisis. According to Cameron Dearlove, the executive director at Porchlight ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Ontario's addictions minister says the best way to curb the entry of people to the opioid epidemic is to treat youth mental ...

Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid​ medications like Vicodin and OxyContin.

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

Unlike opioids, which bind to brain receptors to reduce pain but often lead to dependence and addiction, Journavx works ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

The company tested cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, in a late-stage trial on patients who have undergone cosmetic ...